Efficacy and safety of ormeloxifene in the management of dysfunctional uterine bleeding
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20191933Keywords:
Dysfunctional uterine bleeding, Ormeloxifene, SERMAbstract
Background: The term dysfunctional uterine bleeding (DUB) is used for abnormal uterine bleeding occurring in the absence of identifiable pathology. A number of drugs are available for management of DUB- nonsteroidal anti-inflammatory drugs, tranexamic acid, ethamsylate, hormones like Oral contraceptives progestins etc. The present study was done to determine the efficacy and safety of ormeloxifene in the management of DUB.
Methods: This prospective clinical study involved 50 cases with DUB who were treated with ormeloxifene 60 mg tablet twice a week for first 12 weeks and the once a week for next 12 weeks. They were followed after 6 months of therapy. The outcome was studied by assessment of menstrual blood loss by PBAC score, Hb level in g/dl, endometrial thickness in mm, relief of dysmenorrheal and any side effects of drugs.
Results: The median PBAC score was significantly reduced from 316 to 52 after 6 months of therapy. The mean Hb concentration was significantly increased from 7.8 g/dl to 9.1 g/dl at 6 months of therapy. The mean endometrial thickness was reduced from 10 mm to 7.9 mm after 6 months of therapy. 66% of women showed marked subjective improvement in symptoms. Amenorrhea was the main side effect (12%).
Conclusions: Ormeloxifene has significant effect in reducing endometrial thickness, decreasing the amount of menstrual blood loss, reducing dysmenorrhea and thereby improving the general condition of the patient. It is definitely a better alternative to hysterectomy in women who wish to avoid surgeries and maintain their reproductive functions.
Metrics
References
Fraser IS, Critchley HO, Broder M. The FIGO recommendations on terminologies and definition for normal and abnormal uterine bleeding. In: seminars in reproductive medicine: Thieme Medical Publishers. 2011;29:383-90.
Paula J. Benign disease of female reproductive tract. In: Berek JS (editor). Berek and Novak’s gynaecology. Philadelphia: Lippincott Williams and Wilkins; 591-609.
Padubidri BG, Daftary SN. Howkins and Bourne. Shaw’s textbook of gynaecology.16th ed: Elseiver. 2015;333-48.
Speroff L, Fritz MA. Clinical gynaecologic endocrinology and infertility, 8th ed. 591-609.
Frick KD, Clark MA, Steinwachs DM. Financial and quality of life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Women’s health issues. 2009;19:70-8.
Hallberg L, Hogdahl AM, Nilsson L. Menstrual blood loss- a population study. Variation at different ages and attempts to define normality. Obstet Gynecol Scand.1966;45:320-51.
Gath D, Osborn M, Bungay G. Psychiatric disorder and gynaecological symptoms in middle aged women: A community survey. Br Med J (Clin Res Ed). 1987;294:213-8.
Oehler MK, Rees MC. Menorrhagia: An update. Acta Obstet Gynecol Scand. 2003;82:405-22.
Makker A, Tandon I, Goel MM. Effect of ormiloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects. Fertil Steril. 2009;91:2298-307.
Lal J. Clinical pharmacokinetics and interaction of centchroman- a mini review. Contraception. 2010;81:275-80.
Shelly W, Draper MW, Krishnan V. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163-81.
Higham JM, O’ Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynecol. 1990;734-9.
Biswas SC, Saha SK, Bag TS. Ormeloxifene, a selective estrogen receptor modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynecol. 2004;54:56-9.
Kriplani A, Kulshrestha B, Agarwal N. Efficiency and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynecol Res 2009;35:746-52.
Bhattacharyya TK, Banerji A. Efficacy of selective estrogen receptor modulator: ‘ormeloxifene’ in management of dysfunctional uterine bleeding. South Asian Federal Obstet Gynecol. 2010;2:207-11.
Agarwal N, Singh S, Agarwal M. Comparative evaluation of the efficacy and safety of ormeloxifene and norethistrone in dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2013;2:194-8.